LATEST NEWS

Phase I Publication Call

Fourth Quarter and Full Year 2017 Update Call

2018 The Microcap Conference Presentation

STOCK INFORMATION

TapImmune Inc.

NSDQ: TPIV

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

TapImmune, Inc. is a leader in the TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company’s peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company’s technologies may be used as stand-alone medications or in combination with other treatment modalities.

LATEST PRESENTATION

LATEST FINANCIAL RESULTS

Q4 2017

Quarterly Results, Ended December 31, 2017      

annualReport-10-k

LATEST 10-K

IR CONTACT DETAILS

TapImmune

5 West Forsyth St. Suite 200
Jacksonville, FL 32202
T: (904) 862-6490
investor.relations@tapimmune.com